For example, it has been shown that treatment with a novel broad-spectrum PI3K inhibitor, Compound A, results into the decreased survival, apoptosis induction, and G1 phase arrest of ARP1, ARK, MM.1S, MM.1R, CAG, and U266 myeloma cell lines as well as primary myeloma cells in dose and time-dependent manners.36 In another study, LY294002 treatment inhibited the RPMI 8226 cell migration and VEGF secretion.71 Inhibiting the PI3K signaling pathway using BKM120 inhibitor also resulted into the decreased survival of KMM-1 and RPMI 8226 cells through the caspase-3-dependent apoptosis induction. This evidence concerns the gene VEGFA and plasma cell myeloma.